|Standard of Care Wiki
|Behavior, Addictive NIH
|Substance-Related Disorders NIH
There is one clinical trial.
The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction. The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users
Description: measurement of the difference in drugs consumption caused by containment (delta)Measure: Evolution of consumption Time: 1 day
Description: measurement of the difference in drugs consumption caused by containment (delta)Measure: Evolution of consumption Time: 1 month after confinmant
Description: number of drug users referred to care (%)Measure: health care access Time: 1 day
Description: number of drug users referred to care (%)Measure: health care access Time: 1 month after confinmant
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports